High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination

• Published in: Virology (New York, N.Y.) Vol. 387; no. 2; pp. 414 - 426
• Main Authors: Davis, Katie L., Gray, Elin S., Moore, Penny L., Decker, Julie M., Salomon, Aidy, Montefiori, David C., Graham, Barney S., Keefer, Michael C., Pinter, Abraham, Morris, Lynn, Hahn, Beatrice H., Shaw, George M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.05.2009
• Subjects: Acute Disease; Acute HIV-1 infection; Amino Acid Sequence; Antibody Specificity; Cross Reactions; Epitopes - genetics; Epitopes - immunology; Female; HIV Antibodies - blood; HIV Antibodies - immunology; HIV Envelope Protein gp120 - genetics; HIV Envelope Protein gp120 - immunology; HIV Infections - blood; HIV Infections - immunology; HIV-1; HIV-1 - immunology; HIV-2; HIV-2 - immunology; Human immunodeficiency virus 1; Human immunodeficiency virus 2; Humans; Infectious Disease; Molecular Sequence Data; Neutralization Tests; Neutralizing antibodies; Peptide Fragments - genetics; Peptide Fragments - immunology; Sequence Alignment; Vaccination; Variable loop 3; HIV-1; Variable loop 3; HIV-2; Neutralizing antibodies; Acute HIV-1 infection
• DOI: 10.1016/j.virol.2009.02.022
• ISSN: 0042-6822; 1096-0341

Identifying the earliest neutralizing antibody specificities that are elicited following infection or vaccination by HIV-1 is an important objective of current HIV/AIDS vaccine research. We have shown previously that transplantation of HIV-1 V3 epitopes into an HIV-2 envelope (Env) scaffold provides a sensitive and specific means to detect and quantify HIV-1 V3 epitope specific neutralizing antibodies (Nabs) in human sera. Here, we employ this HIV-2/HIV-1 V3 scaffolding strategy to study the kinetics of development and breadth of V3-specific Nabs in longitudinal sera from individuals acutely infected with clade C or clade B HIV-1 and in human subjects immunized with clade B HIV-1 immunogens. HIV-2/HIV-1 chimeras containing V3 sequences matched to virus type (HIV-2 or HIV-1), subtype (clade B or C), or strain (autologous or heterologous) were used as test reagents. We found that by 3–8 weeks post infection, 12 of 14 clade C subjects had a median IC 50 V3-specific Nab titer of 1:700 against chimeric viruses containing a heterologous clade C V3. By 5 months post-infection, all 14 subjects were positive for V3-specific Nabs with median titers of 1:8000 against heterologous clade C V3 and 1:1300 against clade B V3. Two acutely infected clade B patients developed heterologous clade B V3-specific Nabs at titers of 1:300 and 1:1800 by 13 weeks of infection and 1:5000 and 1:11000 by 7 months of infection. Titers were not different against chimeras containing autologous clade B V3 sequences. Each of 10 uninfected normal human volunteers who were immunized with clade B HIV-1 Env immunogens, but none of five sham immunized control subjects, developed V3-specific Nabs titers as high as 1:3000 (median 1:1300; range 1:700–1:3000). None of the HIV-1 infected or vaccinated subjects had antibodies that neutralized primary HIV-1 virus strains. These results indicate that high-titer, broadly reactive V3-specific antibodies are among the first to be elicited during acute and early HIV-1 infection and following vaccination but these antibodies lack neutralizing potency against primary HIV-1 viruses, which effectively shield V3 from antibody binding to the functional Env trimer.